Results indicate that tirzepatide and semaglutide provide substantial health benefits, including reductions in obesity, ...

WalletHub released a new analysis ranking America's most overweight cities, based on obesity rates, health consequences and ...

A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

Policymakers should focus on both obesity prevention and better access to treatment for those already living with obesity.

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

covering them would financially benefit the state in the long term by reducing the cost of chronic diseases associated with ...

At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles ...

A large majority of older Americans feel that health insurance – including Medicare – should cover anti-obesity medications, according to a new University of Michigan study.